Commentary
Video
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
Author(s):
Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.
Rimas V. Lukas, MD, neuro-oncologist, associate professor, Neurology, Northwestern University Feinberg School of Medicine, discusses key efficacy data and implications from the phase 3 STELLAR trial (NCT02796261) evaluating eflornithine plus lomustine vs lomustine in patients with recurrent IDH-mutant anaplastic astrocytoma per 2021 World Health Organization diagnostic criteria.
Related Videos
Related Content
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
